Production of chimeric antibodies by homologous recombination

• US 5,204,244 A
• Filed: 09/14/1988
• Issued: 04/20/1993
• Est. Priority Date: 10/27/1987
• Status: Expired due to Term

• Current Assignee: Oncogen
• Original Assignee: Oncogen
• Inventors: Folger Bruce, Kim R., Fell, H. Perry
• Primary Examiner(s): Weimar, Elizabeth C.
• Assistant Examiner(s): Chambers, Jasemine C.
• Application Number:
  US07/243,873
• Time in Patent Office: 1,679 Days
• Field of Search: 435/68, 435/172.3, 435/240.2, 435/240.26, 435/240.27, 435/320, 435/69.1, 435/69.6, 530/387
• US Class Current: 435/69.6
• CPC Class Codes: C07K 16/462 Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 15/64 General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Abstract

A process for producing chimeric antibodies using novel recombinant DNA vectors and homologous recombination in vivo is described. The recombinant DNA constructs of the invention can be used to transfect antibody producing cells so that targeted homologous recombination occurs in the transfected cells leading to gene modification and the production of chimeric antibody molecules by the transfected cells.

Claims

1. A method for the production of a cell line expressing a modified antibody molecule comprising:

(a) transfecting an antibody producing lymphoid cell line with a target vector comprising;

(i) a replacement gene to modify a portion of the genomic sequence of the immunoglobulin genes of the lymphoid cell line, and

(ii) a target sequence homologous to a second DNA sequence adjacent to the immunoglobulin sequence to be converted,

so that the replacement gene modifies the immunoglobulin sequence via site specific homologous recombination with genomic chromosomal DNA in vivo; and

(b) selecting a transfectant which produces the modified antibody molecule.

2. The method according to claim 1 in which the immunoglobulin sequence to be modified comprises a constant region gene, or a portion thereof.

3. The method according to claim 2 in which the replacement gene encodes an immunoglobulin constant region, or portion thereof, which differs from the endogenous immunoglobulin gene constant region sequences of the lymphoid cell line.

4. The method according to claim 2 in which the replacement gene encodes an enzyme, toxin, hormone, growth factor or linker.

5. The method according to claim 1 in which the immunoglobulin sequence to be modified comprises the variable region gene, or a portion thereof.

6. The method according to claim 5 in which the replacement gene encodes an immunoglobulin variable region, or portion thereof, which differs from the endogenous immunoglobulin variable region sequences of the lymphoid cell line.

7. The method according to claim 1 in which the immunoglobulin sequence to be modified comprises a heavy chain gene.

8. The method according to claim 7 in which the target sequence is homologous to V, D, J, or switch regions or introns adjacent to the heavy chain gene to be modified.

9. The method according to claim 1 in which the immunoglobulin sequence to be modified comprises a light chain gene.

10. The method according to claim 9 in which the target sequence is homologous to V, D or J regions or introns adjacent to the light chain gene to be modified.

12. The method according to claim 1 or 11 in which the modified antibody molecule comprises a variable region of murine origin and a constant region of human origin.

13. The method according to claim 1 or 11 in which the modified antibody molecule comprises a variable region joined to a enzyme, toxin, hormone, growth factor or linker.

14. The method according to claim 12 in which the lymphoid cell line to be transfected produces monoclonal antibody L6.

15. The method according to claim 13 in which lymphoid cell line to be transfected produces monoclonal antibody L6.

16. The method according to claim 14 in which the lymphoid cell line comprises HB 8677 as deposited with the ATCC.

17. The method according to claim 15 in which the lymphoid cell line comprises HB 8677 as deposited with the ATCC.

20. The method according to claim 13 in which the lymphoid cell line to be transfected produces monoclonal antibody L20.

21. The method according to claim 20 in which the lymphoid cell line comprises HB 8913 as deposited with the ATCC.

11. A method for the production of a modified antibody molecule, comprising:

(a) culturing a modified-antibody-producing cell line which was prepared by transfecting an antibody-lymphoid-producing cell line with a target vector comprising;

(i) a replacement gene to convert a portion of the genomic sequence of the immunoglobulin genes of the lymphoid cell line, and

(ii) a target sequence homologous to a second DNA sequence adjacent to the immunoglobulin sequence to be converted

so that the replacement gene modifies the immunoglobulin sequence via site specific homologous recombination with genomic chromosomal DNA in vivo and the modified antibody is expressed by the transfected cell line; and

(b) isolating the modified antibody molecule from the culture.

18. The method according to claim 22 in which the lymphoid cell line to be transfected produces monoclonal antibody L20.

19. The method according to claim 18 in which the lymphoid cell line comprises HB 8913 as deposited with the ATCC.